Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win

Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases and other areas. LLY's infectious disease deals offer long-term upside, notably with amezosvatein showing superior tolerability to Shingrix, but meaningful revenues are unlikely before 2030. Retatrutide's phase 3 results raise the efficacy bar for obesity drugs, though tolerability issues may limit its uptake versus the better tolerated tirzepatide.